<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Combined oral contraceptive | Management | Contraception - combined hormonal methods | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers starting the combined oral contraceptive pill, and includes information and advice on the available products; when to start it; the efficacy, advantages and disadvantages, risks and possible adverse effects, and key drug interactions; how to manage common problems (such as missed pills); what to do in the event of vomiting or diarrhoea; and the follow up requirements for this method of contraception."/><meta data-react-helmet="true" property="og:description" content="Covers starting the combined oral contraceptive pill, and includes information and advice on the available products; when to start it; the efficacy, advantages and disadvantages, risks and possible adverse effects, and key drug interactions; how to manage common problems (such as missed pills); what to do in the event of vomiting or diarrhoea; and the follow up requirements for this method of contraception."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Combined oral contraceptive | Management | Contraception - combined hormonal methods | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Contraception - combined hormonal methods</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Combined oral contraceptive</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/contraception-combined-hormonal-methods/","name":"Contraception - combined hormonal methods"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/contraception-combined-hormonal-methods/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Combined oral contraceptive"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Contraception - combined hormonal methods: </span><span>Scenario: Combined oral contraceptive</span></h1><p class="page-header__lead"><span>Last revised in January 2021</span></p></div><p class="visually-hidden">Covers starting the combined oral contraceptive pill, and includes information and advice on the available products; when to start it; the efficacy, advantages and disadvantages, risks and possible adverse effects, and key drug interactions; how to manage common problems (such as missed pills); what to do in the event of vomiting or diarrhoea; and the follow up requirements for this method of contraception.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Contraception - combined hormonal methods chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Combined oral contraceptive"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Combined oral contraceptive</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Combined contraceptive patch"><a aria-current="false" href="../combined-contraceptive-patch/index.html"><span class="stacked-nav__content-wrapper">Scenario: Combined contraceptive patch</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Combined contraceptive vaginal ring"><a aria-current="false" href="../combined-contraceptive-vaginal-ring/index.html"><span class="stacked-nav__content-wrapper">Scenario: Combined contraceptive vaginal ring</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#starting-a-coc-pill">Starting a COC pill</a><ol aria-label="Sections within Starting a COC pill" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#assessment">Assessment</a></li><li class=""><a href="index.html#amenorrhea">Amenorrhea</a></li><li class=""><a href="index.html#choice-of-coc">Choice of COC</a></li><li class=""><a href="index.html#when-to-start">When to start</a></li><li class=""><a href="index.html#excluding-pregnancy">Excluding pregnancy</a></li><li class=""><a href="index.html#types-of-coc">Types of COC</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-0e6">Basis for recommendation</a></li></ol></li><li><a href="index.html#information-advice">Information and advice</a><ol aria-label="Sections within Information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#vomiting-diarrhoea">Vomiting and diarrhoea</a></li><li class=""><a href="index.html#pregnancy">Pregnancy</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b1b">Basis for recommendation</a></li></ol></li><li><a href="index.html#advantages-disadvantages">Advantages and disadvantages</a><ol aria-label="Sections within Advantages and disadvantages" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ba1">Basis for recommendation</a></li></ol></li><li><a href="index.html#efficacy">Efficacy</a><ol aria-label="Sections within Efficacy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-18f">Basis for recommendation</a></li></ol></li><li><a href="index.html#risks-adverse-effects">Risks and adverse effects</a><ol aria-label="Sections within Risks and adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#unscheduled-bleeding">Unscheduled bleeding</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-880">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#liver-enzyme-inducing-drugs">Liver-enzyme inducing drugs</a></li><li class=""><a href="index.html#lamotrigine">Lamotrigine</a></li><li class=""><a href="index.html#griseofulvin">Griseofulvin</a></li><li class=""><a href="index.html#additional-drug-interactions">Additional drug interactions</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b94">Basis for recommendation</a></li></ol></li><li><a href="index.html#surgery-or-imobilization">Surgery or imobilization</a><ol aria-label="Sections within Surgery or imobilization" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-14f">Basis for recommendation</a></li></ol></li><li><a href="index.html#follow-up">Follow up</a><ol aria-label="Sections within Follow up" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#duration-of-use">Duration of use</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-b8f">Basis for recommendation</a></li></ol></li><li><a href="index.html#missed-pill-advice">Missed pill advice</a><ol aria-label="Sections within Missed pill advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#missed-coc-pills-except-qlaira-zoely">Missed COC pills except Qlaira and Zoely</a></li><li class=""><a href="index.html#missed-qlaira-pills">Missed Qlaira pills</a></li><li class=""><a href="index.html#missed-zoely-pills">Missed Zoely pills</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4e2">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="combined-oral-contraceptive" class="ChapterBody-module--wrapper--2HCfk "><h2 id="combined-oral-contraceptive" class="visually-hidden">Scenario: Combined oral contraceptive</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d2f9d957-bad3-4692-80fd-b771d18fae71 --><!-- begin field 434b55b0-3290-465a-8b73-acd900aca55e --><p>From age 13 years to 60 years (Female).</p><!-- end field 434b55b0-3290-465a-8b73-acd900aca55e --><!-- end item d2f9d957-bad3-4692-80fd-b771d18fae71 --></div><section aria-labelledby="starting-a-coc-pill" class="ChapterBody-module--wrapper--2HCfk "><h3 id="starting-a-coc-pill">Starting a combined oral contraceptive (COC) pill</h3><section aria-labelledby="assessment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="assessment">How should I assess a woman who is considering starting a combined oral contraceptive (COC)?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 762adb83-b324-4f9d-a39d-a7a700cf8498 --><!-- begin field a6bcd4a7-00cc-4627-bad5-a7a700cf8706 --><ul><li>For information on assessing a woman who is considering starting a combined oral contraceptive (COC), see the section on <a class="topic-reference external-reference" href="../../../contraception-assessment/management/assessment-for-specific-contraceptive-methods/index.html#combined-hormonal-contraception">combined hormonal contraception</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.</li></ul><!-- end field a6bcd4a7-00cc-4627-bad5-a7a700cf8706 --><!-- end item 762adb83-b324-4f9d-a39d-a7a700cf8498 --></div></section><section aria-labelledby="amenorrhea" class="ChapterBody-module--wrapper--2HCfk "><h4 id="amenorrhea">Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d440ec7f-274d-45e9-b71a-a6bf012573d3 --><!-- begin field a59b7da0-337b-4b08-94f0-a6bf012574f4 --><ul><li><strong>If the woman is amenorrhoeic:</strong><ul><li>Start the combined oral contraceptive (COC) at any time, if it is reasonably certain that the woman is not pregnant.<ul><li>Additional contraception is required for 7 days (9 days for Qlaira<sup>®</sup>).</li></ul></li></ul></li><li><strong>If the woman is postpartum and not breastfeeding:</strong><ul><li>Start the COC on day 21 postpartum if no additional risk factors for venous thromboembolism exist.<ul><li>Additional contraception is required for 7 days.</li></ul></li><li>If it has been more than 21 days postpartum and menstrual cycles have returned, start the COC as for other women having menstrual cycles.</li><li>If it has been more than 21 days postpartum and menstrual cycles have not returned, start the COC as for a woman who is amenorrhoeic.</li></ul></li><li><strong>If the woman is postpartum and breastfeeding: </strong><ul><li>Do not start a COC if the woman is less than 6 weeks postpartum.</li><li>After 6 weeks and before 6 months postpartum, start the COC as for postpartum women who are not breastfeeding.</li></ul></li><li><strong>If the woman has had a miscarriage or termination of pregnancy:</strong><ul><li>If gestation is less than 24 weeks, start the COC within 5 days of surgical or the first stage of medical termination, but ideally on day 1 or 2 (except Qlaira<sup>®</sup> and Zoely<sup>®</sup>). No additional contraception is required.<ul><li>Start Qlaira<sup>®</sup> or Zoely<sup>®</sup> on day 1 post-termination. No additional contraception is required.</li><li>If the COC is started at any other time, provided it is reasonably certain that the woman is not pregnant, advise the woman to use a barrier method of contraception (such as condoms) for 7 days (9 days for Qlaira<sup>®</sup>).</li></ul></li><li>If gestation is 24 weeks or more, start the COC as for a woman who is postpartum.</li></ul></li></ul><!-- end field a59b7da0-337b-4b08-94f0-a6bf012574f4 --><!-- end item d440ec7f-274d-45e9-b71a-a6bf012573d3 --></div></section><section aria-labelledby="choice-of-coc" class="ChapterBody-module--wrapper--2HCfk "><h4 id="choice-of-coc">Which combined oral contraceptive (COC) should I offer first-line?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a6358d30-ccaa-4391-a4bb-a6bf01249c3c --><!-- begin field 2666f68c-379f-4205-a777-a6bf01249d43 --><ul><li>First-line options are monophasic preparations containing 30 micrograms of oestrogen, plus either norethisterone or levonorgestrel.</li><li>However, consider the woman's preference, as any combined oral contraceptive (COC) can be offered first-line.</li><li>Prescribe up to 12 months’ supply for women who are initiating or continuing CHC.</li></ul><!-- end field 2666f68c-379f-4205-a777-a6bf01249d43 --><!-- end item a6358d30-ccaa-4391-a4bb-a6bf01249c3c --></div></section><section aria-labelledby="when-to-start" class="ChapterBody-module--wrapper--2HCfk "><h4 id="when-to-start">When can a woman start using a combined oral contraceptive?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 86b0e6be-a5d6-41ab-b605-f97292a35576 --><!-- begin field fc2c7986-8244-4ed1-be3a-51ed1611801c --><p>Specific advice for women who are amenorrhoeic, postpartum, post-termination, or post-miscarriage is summarized in the section <a class="topic-reference internal-reference" href="index.html#amenorrhea">Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</a>.</p><p><strong>If the woman is not currently using a regular method of contraception or using a barrier method (such as condoms):</strong></p><ul><li>Start the combined oral contraceptive (COC) on day 1 of the menstrual cycle. <ul><li>No additional contraception is required.</li></ul></li><li>If the COC is started on days 2–5 of the menstrual cycle: <ul><li>No additional contraception is required unless the woman is starting Qlaira<sup>®</sup> or Zoely<sup>®</sup>.<ul><li>If the woman is starting Qlaira<sup>®</sup>, advise her to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 9 days.</li><li>If the woman is starting Zoely<sup>®</sup>, advise her to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days.</li></ul></li></ul></li><li>If the COC is started at any other time in the menstrual cycle, provided a barrier method has been used consistently and correctly and/or it is reasonably certain that the woman is not pregnant:<ul><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days (9 days for Qlaira<sup>®</sup>).</li><li>Inform the woman that medical advice may differ from that included in the packet of pills, but it is based on good medical practice.</li></ul></li><li>If pregnancy cannot be excluded and the woman wishes to start hormonal contraception without delay:<ul><li>Prescribe the COC and advise the woman to take a pregnancy test no sooner than 3 weeks after the last episode of unprotected sexual intercourse (UPSI).</li></ul></li></ul><p><strong>If the woman is starting a COC after oral emergency contraception:</strong></p><ul><li>For levonorgestrel, advise the woman to start the COC immediately and avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days (9 days if taking Qlaira<sup>®</sup>).</li><li>For ulipristal acetate, advise the woman to start the COC 5 days after taking ulipristal acetate, and to use a barrier method of contraception (such as condoms) for this time and the next 7 days (9 days if taking Qlaira<sup>®</sup>).</li></ul><p><strong>If the woman is switching from another COC, the combined contraceptive patch, or the combined vaginal ring:</strong></p><ul><li>Start the COC on the day after the last active pill, patch, or vaginal ring. There is no need to wait for the next menstrual period. <ul><li>No additional contraception is required.</li></ul></li><li>If the woman decides to take a 7-day hormone free interval (or a 4-day hormone-free interval for Zoely<sup>®</sup>) before starting the new COC, assess the need for additional contraception and emergency contraception. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a> for more information.</li></ul><p><strong>If the woman is switching from a progestogen-only pill (except desogestrel) or </strong><strong>levonorgestrel intrauterine system (LNG-IUS):</strong></p><ul><li>Start the COC at any time in the menstrual cycle provided it is reasonably certain that the woman is not pregnant. <ul><li>There is no need to wait for the next menstrual period.</li></ul></li><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days (9 days for Qlaira®).</li></ul><p><strong>If the woman is switching from the pro</strong><strong>gestogen-only injectable,</strong><strong> or a </strong><strong>d</strong><strong>esogestrel only pill</strong><strong>:</strong></p><ul><li>Start the COC at any time up to when the repeat of injectable is due, or the next day after the progestogen-only pill.  <ul><li>No additional contraception is required.</li></ul></li></ul><p><strong>If the woman is switching from a progestogen-only implant that has been in situ:</strong></p><ul><li>For 3 years or less — advise the woman to start the COC immediately and that no additional contraception is required.</li><li>For more than 3 years, but 4 years or less, and<em> has not</em> had unprotected sexual intercourse (UPSI) within the last 3 weeks and the current pregnancy test is negative — advise the woman to start the COC immediately and avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days.</li><li>For more than 3 years, but 4 years or less and <em>has</em> had UPSI within the last 3 weeks and the current pregnancy test is negative — advise the woman to start the COC immediately and avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days, and take a pregnancy test at 3 weeks.</li></ul><p><strong>If the woman is switching from a copper intrauterine device (Cu-IUD):</strong></p><ul><li>Remove the IUD on day 1–5 of the menstrual cycle and start the COC on the same day (except if starting Qlaira<sup>®</sup>). <ul><li>No additional contraception is required.</li></ul></li><li>If starting Qlaira<sup>®</sup>, remove the IUD on day 1 of the menstrual cycle and start the COC on the same day.<ul><li> No additional contraception is required.</li></ul></li><li>If the IUD is removed at any other time in the menstrual cycle: <ul><li>Advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for the first 7 days of pill taking (9 days for Qlaira<sup>®</sup>).</li></ul></li><li>If the COC is started 7 days <em>before</em> removal of the IUD (9 days for Qlaira<sup>®</sup>):<ul><li>No additional contraception is required. </li></ul></li></ul><!-- end field fc2c7986-8244-4ed1-be3a-51ed1611801c --><!-- end item 86b0e6be-a5d6-41ab-b605-f97292a35576 --></div></section><section aria-labelledby="excluding-pregnancy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="excluding-pregnancy">Excluding pregnancy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 27038ba4-7293-4291-80de-a6bf012553f8 --><!-- begin field 757d131d-ea29-493b-9149-a6bf0125550b --><ul><li>Health professionals can be ‘reasonably certain’ that a woman is not pregnant if there are no signs or symptoms of pregnancy and one or more of the following criteria are met. The woman:<ul><li>Has not had sexual intercourse since the last normal menses.</li><li>Has used a reliable method of contraception correctly and consistently.</li><li>Is within the first 7 days of the onset of a normal menstrual period.</li><li>Is within 4 weeks postpartum for non-breastfeeding women.</li><li>Is within the first 7 days post-termination of pregnancy, or miscarriage.</li><li>Is fully or nearly fully breastfeeding, amenorrhoeic, and less than 6 months postpartum.</li><li>A pregnancy test is performed no sooner than 3 weeks since the last episode of unprotected sexual intercourse (UPSI) and is negative.</li></ul></li></ul><!-- end field 757d131d-ea29-493b-9149-a6bf0125550b --><!-- end item 27038ba4-7293-4291-80de-a6bf012553f8 --></div></section><section aria-labelledby="types-of-coc" class="ChapterBody-module--wrapper--2HCfk "><h4 id="types-of-coc">What types of combined oral contraceptive (COC) are available?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d49ba721-6336-4e1c-88d2-c2b66a8b4d62 --><!-- begin field cc53e24a-5069-4c54-9f3a-f3bdfc6112ef --><ul><li>Combined oral contraceptives (COCs) contain both an oestrogen (usually ethinylestradiol) and a progestogen (such as levonorgestrel, norethisterone, desogestrel, gestodene, or drospirenone) component. Qlaira<sup>®</sup> and Zoely<sup>®</sup> contain estradiol valerate which is metabolized to estradiol, an oestrogen hormone that is also found naturally in the human body.</li><li><strong>COC preparations differ according to</strong><strong>:</strong><ul><li><strong>How the doses vary over the menstrual cycle.</strong><ul><li>In monophasic COCs, the amount of oestrogen and progestogen in each active tablet is constant throughout the cycle.</li><li>In phasic COCs, the amounts of oestrogen and progestogen vary over the cycle. Phasic COCs can be biphasic (contain two different sets of active pills), triphasic (contain three different sets of active pills), or quadraphasic (contain four different sets of active pills).</li></ul></li><li><strong>The dose/strength of oestrogen.</strong><ul><li>Low-strength COCs contain 20 micrograms of ethinylestradiol.</li><li>Standard-strength preparations contain 30–35 micrograms of ethinylestradiol in monophasic COCs and 30–40 micrograms of ethinylestradiol in phased preparations.</li></ul></li><li><strong>The type of progestogen </strong><strong>they contain.</strong></li><li><strong>The presence or absence of a pill-free interval.</strong><ul><li>Most COCs are packaged as calendar strips of 21 active tablets. One tablet is taken daily for 3 weeks; no tablet is taken during the following 7 days (pill-free interval). However, to aid compliance, some products are packed with 21 active tablets and 7 inert or placebo tablets; a tablet is taken every day of the 28-day cycle (no pill-free interval).</li></ul></li></ul></li></ul><p><strong>Table 1.</strong> Combined oral contraceptives (COCs) currently marketed in the UK.</p><table><thead><tr><th colspan="1" scope="col">Oestrogen (micrograms per day unless otherwise stated)</th><th colspan="1" scope="col">Progestogen (micrograms per day unless otherwise stated)</th><th colspan="1" scope="col">Products</th></tr></thead><tbody><tr><td colspan="3"><strong>Low strength oestrogen</strong></td></tr><tr><td colspan="3"><strong>Monophasic combined oral contraceptives</strong></td></tr><tr><td colspan="1">Ethinylestradiol 20</td><td colspan="1">Norethisterone acetate 1000</td><td colspan="1">Loestrin 20<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 20</td><td colspan="1">Desogestrel 150</td><td colspan="1">Mercilon<sup>®</sup>, Gedarel<sup>®</sup> 20/150</td></tr><tr><td colspan="1">Ethinylestradiol 20</td><td colspan="1">Gestodene 75</td><td colspan="1">Femodette<sup>®</sup>, Sunya<sup>®</sup>, Millinette<sup>®</sup> 20/75</td></tr><tr><td colspan="3"><strong>30 micrograms oestrogen, first-line progestogen</strong></td></tr><tr><td colspan="1">Ethinylestradiol 30</td><td colspan="1">Norethisterone acetate 1500</td><td colspan="1">Loestrin 30<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 30</td><td colspan="1">Levonorgestrel 150</td><td colspan="1">Microgynon 30<sup>®</sup>, Microgynon 30 ED<sup>®</sup>, Ovranette<sup>®</sup>, Levest<sup>®</sup>, Rigevidon<sup>®</sup></td></tr><tr><td colspan="3"><strong>35 micrograms oestrogen, first-line progestogen</strong></td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Norethisterone 500</td><td colspan="1">Brevinor<sup>®</sup>, Ovysmen<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Norethisterone 1000</td><td colspan="1">Norimin<sup>®</sup></td></tr><tr><td colspan="1">Mestranol 50*</td><td colspan="1">Norethisterone 1000</td><td colspan="1">Norinyl-1<sup>®</sup></td></tr><tr><td colspan="3"><strong>30–35 micrograms oestrogen, second-line progestogen</strong></td></tr><tr><td colspan="1">Ethinylestradiol 30</td><td colspan="1">Desogestrel 150</td><td colspan="1">Marvelon<sup>®</sup>, Gedarel<sup>®</sup> 30/150</td></tr><tr><td colspan="1">Ethinylestradiol 30</td><td colspan="1">Gestodene 75</td><td colspan="1">Femodene<sup>®</sup>, Femodene ED<sup>®</sup>, Katya<sup>®</sup>, Millinette<sup>®</sup> 30/75</td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Norgestimate 250</td><td colspan="1">Cilest<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 30</td><td colspan="1">Drospirenone 3000</td><td colspan="1">Yasmin<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 30</td><td colspan="1">Desogestrel 150</td><td colspan="1">Alenvona<sup>®</sup></td></tr><tr><td colspan="1">Estradiol 1.5 mg (equivalent to 36 micrograms of ethinylestradiol)</td><td colspan="1">Nomegestrol acetate 2.5 mg</td><td colspan="1">Zoely<sup>®</sup></td></tr><tr><td colspan="3"><strong>Primarily therapy for acne</strong></td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Cyproterone acetate 2000</td><td colspan="1">Generic: co-cyprindiol 2000/35 tablets. Brand names include: Acnocin<sup>®</sup>, Cicafem<sup>®</sup>, Clairette<sup>®</sup>, Dianette<sup>®</sup>, Diva<sup>®</sup></td></tr><tr><td colspan="3"><strong>Biphasic combined oral contraceptives</strong></td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Norethisterone 500 x 7, 1000 x 14</td><td colspan="1">BiNovum<sup>®</sup></td></tr><tr><td colspan="3"><strong>Triphasic combined oral contraceptives</strong></td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Norethisterone 500 x 7, 1000 x 9, 500 x 5</td><td colspan="1">Synphase<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 35</td><td colspan="1">Norethisterone 500 x 7, 750 x 7, 100 x 7</td><td colspan="1">Trinovum<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 30 x 6, 40 x 5, 30 x 10</td><td colspan="1">Levonorgestrel 50 x 6, 75 x 5, 125 x 10</td><td colspan="1">Logynon<sup>®</sup>, Logynon ED<sup>®</sup>, TriRegol<sup>®</sup></td></tr><tr><td colspan="1">Ethinylestradiol 30 x 6, 40 x 5, 30 x 10</td><td colspan="1">Gestodene 50 x 5, 70 x 5, 100 x 10</td><td colspan="1">Triadene<sup>®</sup></td></tr><tr><td colspan="3"><strong>Quadraphasic combined oral contraceptive</strong></td></tr><tr><td colspan="1">Estradiol valerate 3 mg x 2, 2 mg x 22, 1 mg x 2</td><td colspan="1">Dienogest 2 mg x 5, 3 mg x 17</td><td colspan="1">Qlaira<sup>®</sup></td></tr><tr><td colspan="3">ED = every day. * Mestranol is converted in the liver with 70% efficiency to ethinylestradiol; i.e. 50 micrograms of mestranol is pharmacologically equivalent to 35 micrograms of ethinylestradiol.</td></tr><tr><td colspan="3"><strong>Data from:</strong> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 71, 2016</a>]</td></tr></tbody></table><!-- end field cc53e24a-5069-4c54-9f3a-f3bdfc6112ef --><!-- end item d49ba721-6336-4e1c-88d2-c2b66a8b4d62 --></div></section><section aria-labelledby="basis-for-recommendation-0e6" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-0e6">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0e6b74ea-516d-4df8-b5f3-a7a700d57191 --><!-- begin field c0d5d022-4d51-4106-9722-a7a700d57301 --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>], <em>Contraception after pregnancy </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017a</a>], <em>Quick starting contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2010a</a>], and <em>Switching or starting methods of contraception </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2021</a>], the <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>] a statement from the FSRH clinical effectiveness unit [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015a</a>], and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 71, 2016</a>].</p><!-- end field c0d5d022-4d51-4106-9722-a7a700d57301 --><!-- end item 0e6b74ea-516d-4df8-b5f3-a7a700d57191 --></div></section></section><section aria-labelledby="information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="information-advice">What information and advice should I give a woman who is considering using a combined oral contraceptive (COC)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 310ed1c4-b278-4c15-9e9c-b7b4344cabfc --><!-- begin field 0d347302-bf84-4837-a7aa-957d10140e8c --><ul><li><strong>Discuss:</strong><ul><li>The <a class="topic-reference internal-reference" href="../../background-information/mechanism-of-action/index.html">mechanism of action</a> of the combined oral contraceptive (COC).</li><li>The <a class="topic-reference internal-reference" href="index.html#advantages-disadvantages">advantages and disadvantages</a> of the COC.</li><li>The <a class="topic-reference internal-reference" href="index.html#efficacy">efficacy</a> of the COC pill.</li><li>What happens when the COC is stopped — normal fertility returns as soon as the pill is stopped.</li></ul></li><li><strong>Give advice on:</strong><ul><li>The importance of taking the pill regularly at a time of day that will aid adherence.</li><li><a class="topic-reference internal-reference" href="../../background-information/tailored-regimen/index.html">Tailored CHC regimens</a> to broaden contraceptive choice. <ul><li>Advise that tailored regimens are outside the product license, but are supported by the Faculty of Sexual and Reproductive Healthcare (FSRH).  </li><li>Provide clear information (written or digital) to support tailored use. </li></ul></li><li>How to manage <a class="topic-reference internal-reference" href="index.html#missed-coc-pills-except-qlaira-zoely">missed pills</a> and when additional contraception is required.</li><li>What to do if <a class="topic-reference internal-reference" href="index.html#vomiting-diarrhoea">vomiting or diarrhoea</a> occurs after taking the pill.</li><li>Possible <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">risks and adverse effects</a> of the COC including <a class="topic-reference internal-reference" href="index.html#unscheduled-bleeding">menstrual irregularities</a>.</li><li>The possibility of <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a>.<ul><li>Advise the woman to check with a healthcare professional before starting any new drug treatment (including herbal remedies such as St John's wort).</li></ul></li></ul></li><li><strong>Also:</strong><ul><li>Provide written information on the COC — the <a data-hyperlink-id="72b8709d-5990-41be-b295-a93100bebc73" href="http://www.fpa.org.uk/">Family Planning Association</a> provides a useful <a data-hyperlink-id="99ae93e4-bd18-4a72-8b2c-a93100bebdc9" href="http://www.fpa.org.uk/sites/default/files/the-combined-pill-your-guide.pdf">leaflet</a> with information for women using the COC.</li><li>Offer verbal and/or written advice on long-acting reversible contraception (copper intrauterine device, levonorgestrel intrauterine system, progestogen-only injectables, progestogen-only implant, and the combined vaginal ring). For more information, see the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> and <a class="topic-reference external-reference" href="../../../contraception-progestogen-only-methods/index.html">Contraception - progestogen-only methods</a>.</li></ul></li></ul><!-- end field 0d347302-bf84-4837-a7aa-957d10140e8c --><!-- end item 310ed1c4-b278-4c15-9e9c-b7b4344cabfc --></div><section aria-labelledby="vomiting-diarrhoea" class="ChapterBody-module--wrapper--2HCfk "><h4 id="vomiting-diarrhoea">How should vomiting or diarrhoea be managed in women taking a combined oral contraceptive (COC)?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ba28ed4d-ef12-441f-811d-148fdab97540 --><!-- begin field 94946029-3617-46b1-8dca-634dd83e76a8 --><ul><li><strong>For all combined oral contraceptives (COCs) except Qlaira<sup>®</sup> and Zoely<sup>®</sup>:</strong><ul><li>If a woman vomits (for any reason) within 3 hours of taking a combined oral contraceptive (COC), advise her to take another pill as soon as possible.</li><li>If vomiting or diarrhoea persists for more than 24 hours, advise her:<ul><li>To follow the instructions for <a class="topic-reference internal-reference" href="index.html#missed-coc-pills-except-qlaira-zoely">missed pills</a>, counting each day of vomiting and/or diarrhoea as a missed pill.</li><li>To avoid sexual intercourse or use a barrier method of contraception (such as condoms) during the illness interval and for 7 days afterwards.</li><li>That if the illness occurs while taking the last 7 pills, she should omit any pill-free interval (or inactive tablets) and start the next cycle immediately.</li></ul></li></ul></li><li><strong>For Qlaira<sup>®</sup> and Zoely<sup>®</sup>:</strong><ul><li>If a woman vomits within 3–4 hours of taking an active pill, advise her to take the next tablet as soon as possible, ideally within 12 hours of the usual time of pill taking for Qlaira<sup>®</sup> or 24 hours for Zoely<sup>®</sup>.</li><li>If more than 12 hours elapse for Qlaira<sup>®</sup> or 24 hours for Zoely<sup>®</sup>, advise the woman to follow the <a class="topic-reference internal-reference" href="index.html#missed-qlaira-pills">missed pills</a> advice for Qlaira<sup>®</sup> or <a class="topic-reference internal-reference" href="index.html#missed-zoely-pills">missed pills</a> advice for Zoely<sup>®</sup>.</li><li>If the woman does not want to change her normal pill taking schedule, advise her to take the corresponding pill(s) needed from another pack.</li></ul></li></ul><!-- end field 94946029-3617-46b1-8dca-634dd83e76a8 --><!-- end item ba28ed4d-ef12-441f-811d-148fdab97540 --></div></section><section aria-labelledby="pregnancy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="pregnancy">How should I manage a woman who becomes pregnant whilst taking a combined oral contraceptive (COC)?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 31e76922-3153-4ca4-8d96-888eb4ab5f48 --><!-- begin field 62ec09af-0abc-4264-a497-4d3e66d681f3 --><ul><li>If a woman becomes pregnant while taking the combined oral contraceptive (COC) pill and she wishes to continue with the pregnancy:<ul><li>Advise her to stop taking the pill.</li><li>Inform her that there is no evidence of harm to the baby or the mother if pregnancy occurs whilst using the COC.</li></ul></li></ul><!-- end field 62ec09af-0abc-4264-a497-4d3e66d681f3 --><!-- end item 31e76922-3153-4ca4-8d96-888eb4ab5f48 --></div></section><section aria-labelledby="basis-for-recommendation-b1b" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b1b">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b1bf21a1-2214-4088-97e0-a7a700d1c515 --><!-- begin field 730d1bea-19bc-461b-ac21-a7a700d1c75b --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019</a>], <em>UK Medical Eligibility Criteria for contraceptive use </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>], <em>Drug interactions with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017b</a>], and the manufacturer's Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016b</a>].</p><h5>Advice about tailored CHC regimens</h5><ul><li><p>The traditional 21/7 CHC regimen with a monthly withdrawal bleed confers no health benefit over other patterns of CHC use. Symptoms associated with the hormone-free interval (HFI) can be problematic and ovarian activity during a 7-day HFI could risk escape ovulation (particularly with lower doses of EE and if use is not perfect). Tailored CHC regimens can be safely used to avoid withdrawal bleeds and associated symptoms and theoretically reduce the risk of contraceptive failure [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019</a>]. </p></li></ul><p><strong>Safety of tailored regimens </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019</a>]</p><ul><li>Direct data comparing risk of cardiovascular events and cancer between extended and standard CHC regimens are lacking, however, the FSRH states that indirect evidence regarding cardiovascular risk is reassuring.<ul><li>In a Phase 3 trial of 20 micrograms ethinylestradiol/drospirenone (EE/DRSP) combined oral contraceptive (COC), 1067 women were randomised to standard cyclical, flexible extended or fixed extended pill-taking regimens for 1 year. A total of 755 women then entered an extension phase, taking the flexible extended regimen. Metabolic and haemostatic parameters, serum hormone levels and blood pressure were similar in all groups. Numbers of serious adverse events were very low in all groups.</li><li>A smaller trial which randomised 78 women to use extended or standard cyclical regimens of 30 micrograms EE/DRSP COC found no statistically significant differences in carbohydrate or lipid profiles between the two groups over 6 months of use.</li><li>In a third trial, 174 women were randomised to cyclical or continuous use of 20 micrograms EE/levonorgestrel (LNG) COC (the dose of LNG was different in the two groups). The authors concluded that after 13 months of use, carbohydrate metabolism, lipid profile and haemostatic variables were broadly similar between the groups, but that further studies would be required to assess long-term continuous CHC. Haemostatic parameters were reported to be similar for 187 women randomised to extended or cyclical use of 30 micrograms EE/LNG COC for 6 months.</li></ul></li></ul><p><strong>Bleeding patterns with extended CHC regimens </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019</a>]</p><ul><li>A Cochrane Review of randomized controlled trials (RCTs) reported that in most studies bleeding patterns with extended CHC regimens were equivalent or improved compared to standard regimens.</li><li>A systematic review that included both RCTs and observational studies concluded that overall, the total number of days of bleeding was lower with continuous or extended regimens than with cyclical use of CHC. However, there was an increase in breakthrough bleeding during the first months of use of continuous or extended regimens, its frequency and intensity subsequently decreased over time.</li><li>Limited evidence suggests that bleeding patterns with continuous or extended use of the combined transdermal patch (CTP) and combined vaginal ring (CVR) show a similar reduction in bleeding/spotting days over time to that seen with extended use of COC.</li><li>One study compared bleeding patterns in 139 existing cyclic COC users who were randomised to continuous use for 180 days of COC containing 30 micrograms EE/100 micrograms LNG, 20 micrograms EE/100 micrograms LNG, 30 micrograms EE/1000 micrograms norethisterone (NET) or 20 micrograms EE/1000 micrograms NET (only the first of these is available in the UK). The study suggested more favourable bleeding patterns (more amenorrhoea and fewer spotting days) with continuous use of NET COC than with continuous use of LNG COC. The authors noted that the study findings did not support use of higher EE doses to prevent breakthrough bleeding during continuous COC use. It is not known how bleeding patterns with continuous use of other COC would compare.</li></ul><p><strong>Tailored regimens and HFI-associated symptoms </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019</a>]</p><ul><li>A Cochrane Review<font size="1"> </font>of RCTs identified studies that reported improvement in menstrual-related headache, bloating, tiredness and menstrual pain with extended COC regimens.</li><li>Observational studies similarly suggest benefit. <ul><li>A cohort study of 111 women who reported cyclical symptoms with two cycles of use of a 21/7 COC regimen found that mood, headache and pelvic pain scores improved significantly after the women switched to an extended COC regimen and were followed up for a year — 80% of the women continued the extended regimen for the full year, and 6 months after that most women reported that they had continued the extended regimen on their own.</li><li>A prospective cohort study of 109 women given 30 micrograms EE/DRSP COC for two 21/7 cycles, followed by two 84/7 cycles (two-thirds completed all cycles) reported a significantly reduced incidence of heavy menstrual bleeding (HMB), intermenstrual bleeding, dysmenorrhoea, abdominal bloating, depressed mood and irritability at the end of the second 84/7 cycle compared to at enrolment.</li></ul></li></ul><p><strong>Return to fertility after tailored regimens </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2019</a>]</p><ul><li><p>One study found that of 187 women aged 18–49 years who had used continuous 20 micrograms EE/ LNG COC for at least 6 months, 98.9% returned to spontaneous menstruation or became pregnant within 90 days. In another study, amongst 47 women who had used 20 micrograms EE/LNG COC continuously for 84 days, ovulation was observed within 37 days of stopping treatment in all but one case (98%).</p></li></ul><!-- end field 730d1bea-19bc-461b-ac21-a7a700d1c75b --><!-- end item b1bf21a1-2214-4088-97e0-a7a700d1c515 --></div></section></section><section aria-labelledby="advantages-disadvantages" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advantages-disadvantages">What are the advantages and disadvantages associated with combined oral contraceptives (COCs)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 32853d0c-6abf-40c0-9a98-c6acbf1a16fd --><!-- begin field 4b58ac87-105b-401c-801e-7f509a5fc0c3 --><h4>Advantages</h4><ul><li>Combined oral contraceptive (COCs) are more effective at preventing pregnancy than barrier methods. For more information, see the section on <a class="topic-reference external-reference" href="../../../contraception-assessment/background-information/comparative-effectiveness-of-contraceptive-methods/index.html">comparative efficacy</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>. </li><li>Sexual intercourse need not be interrupted to use COCs.</li><li>Menstrual bleeding is usually regular, lighter, and less painful.</li><li>There is a reduced risk of about 50% for ovarian and endometrial cancer that continues for several decades after stopping the COC.  </li><li>There is a reduced risk of colorectal cancer and of functional ovarian cysts and benign ovarian tumours.</li><li>There is reduced severity of acne in some women.</li><li>Normal fertility returns immediately after stopping the COC.</li><li>COCs may also reduce the risk of benign breast disease and osteoporosis, although the available evidence is conflicting.</li></ul><h4>Disadvantages</h4><ul><li>Some women experience temporary <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">adverse effects</a> when they start COCs.</li><li>The COC does not protect against sexually transmitted infections (STIs); people at risk of STIs are advised to use condoms in addition to the COC.</li><li>They are less effective than long-acting reversible methods of contraception (progestogen-only implants or injectables, copper intrauterine devices, levonorgestrel intrauterine system and the combined vaginal ring).</li></ul><!-- end field 4b58ac87-105b-401c-801e-7f509a5fc0c3 --><!-- end item 32853d0c-6abf-40c0-9a98-c6acbf1a16fd --></div><section aria-labelledby="basis-for-recommendation-ba1" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ba1">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ba11f54d-109d-45fd-a65f-9319d0191ceb --><!-- begin field 8572e557-fe1e-4b3a-b2ec-c866a8d8bdcd --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>].</p><!-- end field 8572e557-fe1e-4b3a-b2ec-c866a8d8bdcd --><!-- end item ba11f54d-109d-45fd-a65f-9319d0191ceb --></div></section></section><section aria-labelledby="efficacy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="efficacy">How effective are combined oral contraceptive (COCs) at preventing pregnancy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5beb1bbe-7c78-4a4e-bb24-58589789c75b --><!-- begin field 42cd4310-dcf7-4332-a8f7-3c935cffbce6 --><ul><li>For a comparison of the efficacy of combined oral contraceptives (COCs) with other methods, see the section on <a class="topic-reference external-reference" href="../../../contraception-assessment/background-information/comparative-effectiveness-of-contraceptive-methods/index.html">How effective are the available contraceptive methods?</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.<ul><li>When the COC is used perfectly (consistently and correctly), 0.3% of women will conceive within the first year of use due to method failure.</li><li>When the COC is used typically, 9% will conceive within the first year of use due to method failure or user failure.</li><li>Clinical trials suggest that Qlaira<sup>®</sup> and Zoely<sup>®</sup> are as effective as other types of COCs. </li></ul></li></ul><!-- end field 42cd4310-dcf7-4332-a8f7-3c935cffbce6 --><!-- end item 5beb1bbe-7c78-4a4e-bb24-58589789c75b --></div><section aria-labelledby="basis-for-recommendation-18f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-18f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 18feb3b4-c312-48e5-af69-01a6db54ffad --><!-- begin field 2c034aff-c13f-4112-9418-7f016c32f03e --><p>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>] and a National Institute for Health and Care Excellence (NICE) new medicine evidence summary <em>Combined oral contraception: nomegestrol/</em><em>estradiol (Zoely) </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013</a>].</p><!-- end field 2c034aff-c13f-4112-9418-7f016c32f03e --><!-- end item 18feb3b4-c312-48e5-af69-01a6db54ffad --></div></section></section><section aria-labelledby="risks-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="risks-adverse-effects">What are the risks and adverse effects of combined oral contraceptives?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 90c4eb10-efb0-4d3b-a5a4-7fd907d565a7 --><!-- begin field e8fb3a33-5ff1-4774-a165-77fdce310dc7 --><ul><li><strong>The most commonly reported adverse effects are</strong>: <ul><li>Nausea and abdominal pain.</li><li>Headache.</li><li>Breast pain and/or tenderness.</li><li>Menstrual irregularities — up to 20% of COC users have <a class="topic-reference internal-reference" href="index.html#unscheduled-bleeding">irregular bleeding</a>. </li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Hypertension.</li><li>Changes in lipid metabolism.</li></ul></li><li><strong>Cardiovascular disease and stroke</strong><ul><li>Hypertension, myocardial infarction (MI), and stroke — there is a very small increase in risk of MI, and two-fold increase in risk of stroke in women using the COC (200 per 100,000 women) compared to women not using COCs (100 per 100,000 women).<ul><li>The risk is greatest in women who smoke, and women with diabetes, hypertension, a body mass index (BMI) of 35 kg/m2 or more, migraines with aura, or a family history of premature atherosclerotic cardiovascular disease.</li></ul></li></ul></li><li><strong>Venous thromboembolism (VTE)</strong><ul><li>There is an increased risk of VTE with COC users compared with non-users, but the absolute risk is very low and is considerably less than the risk of VTE in pregnancy (29 per 10,000 women years compared with 5–12 per 10,000 women years for COC users).</li><li>The risk of VTE associated with different COCs is influenced by the progestogen component:<ul><li>COCs containing levonorgestrel, norethisterone, or norgestimate have the lowest risk (5–7 per 10,000 women years) and those containing drospirenone, desogestrel, or gestodene have the highest risk (9–12 per 10,000 women years).</li></ul></li></ul></li><li><strong>Breast cancer</strong><ul><li>There is a possible small increased risk of breast cancer (relative risk [RR] 1.24, 95% confidence interval [CI] 1.15–1.33), which returns to normal within 10 years after stopping the COC.</li></ul></li><li><strong>C</strong><strong>ervical cancer</strong><ul><li>The increased risk is related to duration of use.<ul><li>There is a small increased risk after 5 years and a two-fold increase after 10 years. </li><li>The risk returns to normal 10 years after stopping the COC.</li></ul></li><li>Advise women to attend routine cervical cytology screening.</li></ul></li><li><strong>Mood changes </strong><ul><li>Depressed mood/depression are known side effects of hormone contraceptive use. The manufacturer SPCs states that it can be serious and is a risk factor for suicidal behaviour/suicide. Women are advised to seek medical help in case of mood changes whilst taking combined norethisterone and ethinylestradiol (norimin or synphase) tablets [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019b</a>].</li></ul></li><li><strong>There is no evidence that COCs cause: </strong><ul><li>Weight gain.</li><li>Loss of libido.</li></ul></li><li><strong>Liver disease</strong> — co-cyprindiol is contraindicated in women with severe hepatic disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</li><li><strong>Meningioma </strong>— the occurrence of meningiomas (single and multiple) has been reported in association with use of cyproterone acetate, especially at high doses of 25 mg and above and for prolonged time. If a patient is diagnosed with meningioma, any cyproterone containing treatment, including co-cyprindiol, must be stopped, as a precautionary measure [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BJCP, 2018</a>]</p><!-- end field e8fb3a33-5ff1-4774-a165-77fdce310dc7 --><!-- end item 90c4eb10-efb0-4d3b-a5a4-7fd907d565a7 --></div><section aria-labelledby="unscheduled-bleeding" class="ChapterBody-module--wrapper--2HCfk "><h4 id="unscheduled-bleeding">How should I manage unscheduled bleeding in a woman using the combined oral contraceptive?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7268b320-50ac-4f9c-882e-a6c00119b59d --><!-- begin field e3507dfa-28fb-4601-82de-a6c00119b6b5 --><ul><li><strong>Exclude and/or manage:</strong><ul><li>Situations which could compromise the effectiveness of the COC, such as <a class="topic-reference internal-reference" href="index.html#missed-coc-pills-except-qlaira-zoely">missed pills</a>, <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a>, and <a class="topic-reference internal-reference" href="index.html#vomiting-diarrhoea">vomiting or diarrhoea</a>.</li><li>Situations which could result in unscheduled bleeding, such as:<ul><li>Sexually transmitted infections (STIs) — as a minimum, test for <em>Chlamydia trachomatis</em>. The risk of STIs is increased if the woman is under 25 years of age, has a new sexual partner, or has had more than one sexual partner in the last year. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a>.</li><li>Pregnancy — perform a pregnancy test.</li><li>Gynaecological conditions such as cervical cancer — if this is suspected, refer the woman using a suspected cancer pathway referral (for an appointment within 2 weeks). For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gynaecological-cancers-recognition-referral/index.html">Gynaecological cancers - recognition and referral</a>.</li><li>Endometrial cancer — refer women aged 45 and older using a suspected cancer pathway referral (for an appointment within 2 weeks) if they have unscheduled bleeding. Refer women younger than 45 years if they have risk factors for endometrial cancer and persistent, problematic bleeding after the first 3 months of use, or if they present with a change in bleeding pattern after at least 3 months of use. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gynaecological-cancers-recognition-referral/index.html">Gynaecological cancers - recognition and referral</a>.</li></ul></li></ul></li><li><strong>Consider performing a speculum and pelvic examination:</strong><ul><li>For persistent bleeding beyond the first 3 months of use — unscheduled bleeding is common in the first 3 months of starting a new hormonal contraceptive method.</li><li>For new symptoms or a change in bleeding after at least 3 months of use.</li><li>If the woman has not participated in the NHS Cervical Screening programme regularly. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../cervical-cancer-hpv/index.html">Cervical cancer and HPV</a>.</li><li>If requested by the woman.</li><li>If there are other symptoms such as pelvic pain, dyspareunia, or post-coital bleeding. </li></ul></li><li>If no other underlying cause of irregular bleeding is suspected, and speculum and pelvic examination is normal, the bleeding can be assumed to be caused by the COC. Providing the woman has no other symptoms:<ul><li>Reassure her that unscheduled bleeding is common in COC users.</li><li>Encourage new users of the COC to persevere with use for up to 3 months.</li><li>If bleeding does not settle, consider one of the following options:<ul><li>Change to a different COC (with a higher dose of oestrogen, or higher dose of progestogen, or different type of progestogen).</li><li>Change to another form of contraception — there may be less unscheduled bleeding with the <a class="topic-reference internal-reference" href="../combined-contraceptive-vaginal-ring/index.html">combined vaginal ring</a>.</li></ul></li></ul></li></ul><!-- end field e3507dfa-28fb-4601-82de-a6c00119b6b5 --><!-- end item 7268b320-50ac-4f9c-882e-a6c00119b59d --></div></section><section aria-labelledby="basis-for-recommendation-880" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-880">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8800fce3-3000-48a1-9bd2-d5a13bc4a64c --><!-- begin field 065aea48-a6fd-4111-b914-12a694bf723a --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>] and <em>Problematic</em><em> bleeding with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015b</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Suspected cancer: recognition and referral </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>], an FSRH statement on <em>Venous thromboembolism and hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014</a>], information in the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 71, 2016</a>], and the manufacturer's Summary of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015</a>].</p><h5>Endometrial cancer</h5><ul><li>NICE advises considering using a suspected cancer pathway referral (for an appointment within 2 weeks) for women aged under 55 years with post-menopausal bleeding. However, the FSRH advises that an endometrial biopsy should be considered in women aged 45 years or over and in women under 45 years with risk factors for endometrial cancer who have persistent problematic bleeding after the first 3 months of use of a method or who present with a change in bleeding pattern [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>].</li></ul><!-- end field 065aea48-a6fd-4111-b914-12a694bf723a --><!-- end item 8800fce3-3000-48a1-9bd2-d5a13bc4a64c --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What are the key drug interactions for combined oral contraceptive (COCs) and how should I manage them?</h3><section aria-labelledby="liver-enzyme-inducing-drugs" class="ChapterBody-module--wrapper--2HCfk "><h4 id="liver-enzyme-inducing-drugs">Liver enzyme-inducing drugs</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 132a11c7-71cd-4b2c-ad9e-4cbc3bbe13d8 --><!-- begin field 406db60a-471f-4880-84fb-e5f2cb947820 --><ul><li>Advise the woman that liver enzyme-inducing drugs may reduce the efficacy of the combined oral contraceptive (COC) pill. Examples of liver enzyme-inducing drugs are:<ul><li>Antibiotics — rifampicin and rifabutin are very potent enzyme inducers.</li><li>Antiepileptic drugs such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, and topiramate.<ul><li>Topiramate is associated with a risk of fetal malformations and can impair the effectiveness of hormonal contraceptives. Before initiating topiramate in a woman of childbearing potential, pregnancy testing should be performed. The patient should be fully informed of the risks related to the use of topiramate during pregnancy. Ensure that women and girls of childbearing potential are advised that they should be using a highly effective method of contraception. Topiramate is a weak enzyme inducer, but the contraceptive efficacy of the COC may be unaffected by topiramate doses lower than 200 mg daily [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017</a>].</li></ul></li><li>Antiretrovirals such as ritonavir, ritonavir-boosted protease inhibitors, efavirenz, and nevirapine.</li><li>St John's wort.<ul><li>Advise women taking a COC not to take herbal products containing St John’s wort.</li></ul></li></ul></li></ul><p><strong>If a woman is on short-term treatment (2 months or less) with a liver enzyme-inducing drug:</strong></p><ul><li>Always advise her to change to an alternative contraceptive method if she is taking rifampicin or rifabutin. <ul><li>For example having a one-off progestogen-only injection to cover the short-term treatment and for 28 days after.</li></ul></li><li>If the woman would like a choice with other enzyme-inducing drugs, consider one of the following options:<ul><li>Advise the woman to continue using the COC (containing at least 30 micrograms of ethinylestradiol). In order to minimize the risk of contraceptive failure, she should use an extended or tricycling regimen with a pill-free interval of 4 days.<ul><li>Also advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) while taking, and for 28 days after stopping, the liver enzyme-inducing drug.</li></ul></li><li>Advise the woman to take two COC pills containing at least 50 micrograms of ethinylestradiol (for example taking both a 20 microgram and a 30 microgram COC or two 30 microgram COCs) during treatment with the liver enzyme-inducing drugs (except with potent inducers, rifampicin and rifabutin) and for 28 days after, using an extended or tricycling regimen, with a pill-free interval of 4 days.<ul><li>No additional contraception is required.</li></ul></li></ul></li><li>Consider the need for emergency contraception if sexual intercourse has taken place while the efficacy of the COC may have been reduced, for example if the woman has already started treatment with a liver enzyme-inducing drug. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a> for more information.</li></ul><p><strong>If a woman is on long-term treatment (longer than 2 months) with a liver enzyme-inducing drug:</strong></p><ul><li>Always advise her to change to an alternative contraceptive method if she is taking rifampicin or rifabutin. </li><li>If the woman would like a choice with other enzyme-inducing drugs, advise her to take two COC pills containing at least 50 micrograms of ethinylestradiol (for example taking both a 20 microgram and a 30 microgram COC or two 30 microgram COCs) during treatment with the liver enzyme-inducing drug and for 28 days after, using an extended or tricycling regimen, with a pill-free interval of 4 days.<ul><li>No additional contraception is required.</li><li>Note: Taking two COCs, extended/tricycling regimens and shortening the pill-free interval are all outwith the product licence and there is no evidence that such practice is effective in women taking enzyme-inducing drugs.</li></ul></li><li>Be aware that breakthrough bleeding may indicate low serum ethinylestradiol concentrations. If it occurs, exclude <a class="topic-reference internal-reference" href="index.html#unscheduled-bleeding">other causes of bleeding</a> (such as a sexually transmitted infection) and increase the dose of ethinylestradiol up to a maximum of 70 micrograms.</li><li>Consider the need for emergency contraception if sexual intercourse has taken place while the efficacy of the COC may have been reduced, for example if the woman has already started treatment with a liver enzyme-inducing drug. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a> for more information.</li></ul><h5>Extended or tricycling regimen</h5><ul><li>Only monophasic 21-day pill packs are suitable for the extended or tricycling regimen and the COC should contain at least 30 micrograms of ethinylestradiol.<ul><li>For more information on monophasic pills, see the section on <a class="topic-reference internal-reference" href="index.html#types-of-coc">types of combined oral contraceptive pill</a>. </li></ul></li><li>To reduce the risk of contraceptive failure, an extended or tricycling regimen, with a shortened pill-free interval of 3–4 days can be used: <ul><li>An extended regimen means using the COC continuously for 3 weeks or more, until breakthrough bleeding occurs for 3 to 4 days.</li><li>A tricycling regimen means taking 3 pill packs continuously without a break.</li></ul></li></ul><!-- end field 406db60a-471f-4880-84fb-e5f2cb947820 --><!-- end item 132a11c7-71cd-4b2c-ad9e-4cbc3bbe13d8 --></div></section><section aria-labelledby="lamotrigine" class="ChapterBody-module--wrapper--2HCfk "><h4 id="lamotrigine">Lamotrigine</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1113a2b6-71e3-4181-b2b2-bec040b0993f --><!-- begin field df2e4de2-581a-4ae9-a220-999266463172 --><ul><li>If the woman is taking lamotrigine monotherapy, advise her to change to an alternative method of contraception, as concurrent use with the combined oral contraceptive (COC) may lower the seizure control.</li><ul><li>If the woman still wishes to use the COC:</li><ul><li>Seek specialist advice, as the maintenance dose of lamotrigine may need to be increased as much as two-fold, according to clinical response.</li></ul><li>Advise the woman to seek medical advice before stopping the COC.</li><ul><li>The maintenance dose of lamotrigine may need to be decreased by as much as 50% if the COC is stopped, according to clinical response and lamotrigine adverse effects,</li></ul></ul><li>If the woman is taking lamotrigine plus sodium valproate, the COC is unlikely to affect seizure control.</li><li>If the woman is taking lamotrigine plus an antiepileptic drug that induces liver enzymes (such as carbamazepine), follow the advice in the section on <a class="topic-reference internal-reference" href="index.html#liver-enzyme-inducing-drugs">Liver enzyme-inducing drugs</a>.</li></ul><!-- end field df2e4de2-581a-4ae9-a220-999266463172 --><!-- end item 1113a2b6-71e3-4181-b2b2-bec040b0993f --></div></section><section aria-labelledby="griseofulvin" class="ChapterBody-module--wrapper--2HCfk "><h4 id="griseofulvin">Griseofulvin</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e570d387-9eb9-4d28-90a7-a70b00fce548 --><!-- begin field f30f6bf3-9cca-416e-9f08-a70b00fce726 --><p><strong>If a woman is taking griseofulvin:</strong></p><ul><li>Advise the woman that griseofulvin may reduce the efficacy of the combined oral contraceptive (COC) pill, and to change to an alternative contraceptive method. <ul><li>For example having a one-off progestogen-only injection to cover the short-term treatment and for 28 days after.</li></ul></li><li>If this is not acceptable or possible, then consider the following option:<ul><li>Advise the woman to take two COC pills containing at least 50 micrograms of ethinylestradiol (for example taking both a 20 microgram and a 30 microgram COC or two 30 microgram COCs) during treatment with the griseofulvin and for 28 days after, using an extended or tricycling regimen, with a pill-free interval of 4 days.<ul><li>As there is a theoretical risk of teratogenic effects with griseofulvin, also recommend the use of condoms during treatment and for the following 28 days. </li></ul></li></ul></li><li>Be aware that breakthrough bleeding may indicate low serum ethinylestradiol concentrations. If it occurs, exclude <a class="topic-reference internal-reference" href="index.html#unscheduled-bleeding">other causes of bleeding</a> (such as a sexually transmitted infection) and increase the dose of ethinylestradiol up to a maximum of 70 micrograms.</li><li>Consider the need for emergency contraception if sexual intercourse has taken place while the efficacy of the COC may have been reduced, for example if the woman has already started treatment with griseofulvin. See the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a> for more information.</li></ul><h5>Extended or tricycling regimen</h5><ul><li>Only monophasic 21-day pill packs are suitable for the extended or tricycling regimen and the COC should contain at least 30 micrograms of ethinylestradiol.<ul><li>For more information on monophasic pills, see the section on <a class="topic-reference internal-reference" href="index.html#types-of-coc">types of combined oral contraceptive pill</a>. </li></ul></li><li>To reduce the risk of contraceptive failure, an extended or tricycling regimen, with a shortened pill-free interval of 3–4 days can be used: <ul><li>An extended regimen means using the COC continuously for 3 weeks or more, until breakthrough bleeding occurs for 3 to 4 days.</li><li>A tricycling regimen means taking 3 pill packs continuously without a break.</li></ul></li></ul><!-- end field f30f6bf3-9cca-416e-9f08-a70b00fce726 --><!-- end item e570d387-9eb9-4d28-90a7-a70b00fce548 --></div></section><section aria-labelledby="additional-drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h4 id="additional-drug-interactions">Additional drug interactions</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4dd3182e-65e9-467c-985e-fffc5bbabec1 --><!-- begin field f9c4a23a-a54a-4392-998e-de1280278a9d --><ul><li><strong>The following additional drug interactions may occur with combined oral contraceptives (COCs):</strong><ul><li>Orlistat — advise women on what to do if they experience <a class="topic-reference internal-reference" href="index.html#vomiting-diarrhoea">diarrhoea</a> while taking orlistat.</li><li>Colesevelam — decreases blood concentrations of the COC by binding to COCs in the gut and reducing absorption.<ul><li>Advise women to take the COC 4 hours before taking colesevelam.</li></ul></li><li>Ulipristal acetate — may reduce the efficacy of progestogen-containing contraceptives. The manufacturers of Esmya® (ulipristal acetate 5 mg) advise avoiding concomitant use.</li><li>Antihypertensives — the hypotensive effect may be antagonized. <ul><li>Monitor blood pressure, and adjust the dose of antihypertensive medication accordingly.</li></ul></li><li>Antidiabetic drugs — oestrogens and progestogens antagonize the hypoglycaemic effect. <ul><li>Monitor blood glucose.</li></ul></li><li>Antifungals (such as fluconazole, itraconazole, ketoconazole, voriconazole) — modest increase in plasma levels of oestrogens and/or progestogens. Possible increased risk of adverse effects.</li><li>Drugs to treat hepatitis C — the combination of hormonal contraceptives containing ethinylestradiol and products containing ombitasvir/paritaprevir/ritonavir (Viekirax) and dasabuvir with or without ribavirin, may increase risk of ALT elevations.</li><li>Erythromycin — modest to marked increase in plasma levels of oestrogens and/or progestogens. Possible increase risk of adverse effects.</li><li>Etoricoxib —oestrogen levels increased by around 40% with etoricoxib doses of 60 mg or more. Increased risk of adverse effects.</li><li>Statins — minor to modest increase in plasma levels of oestrogens and/or progestogens. Not likely to be clinically significant. </li><li>Diuretics — oestrogens may antagonize the diuretic effect. The dose of diuretic may need to be adjusted.</li><li>Levothyroxine — oestrogens may increase the requirements for thyroid hormones. <ul><li>Monitor thyroid function, and adjust the dose of levothyroxine accordingly.</li></ul></li><li>Theophylline — oestrogens reduce the excretion of theophylline. <ul><li>The theophylline dose may need to be reduced.</li></ul></li><li>Selegiline — oestrogens and progestogens may increase plasma levels of selegiline, leading to increased risk of toxicity. Avoid concomitant use.</li><li>Tacrolimus — oestrogens, norethisterone enantate, and gestodene may increase tacrolimus levels. <ul><li>Monitor serum tacrolimus levels. </li></ul></li><li>Retinoids — the adverse effect of COCs on lipid levels may be additive with isotretinoin. <ul><li>Monitor lipid levels. </li></ul></li><li>Triptans — COCs appear to modestly raise the levels of frovatriptan, naratriptan, and zolmitriptan and slightly increase levels of sumatriptan. <ul><li>Combined hormonal contraceptives should not be used in women who have migraine with aura.</li></ul></li></ul></li></ul><!-- end field f9c4a23a-a54a-4392-998e-de1280278a9d --><!-- end item 4dd3182e-65e9-467c-985e-fffc5bbabec1 --></div></section><section aria-labelledby="basis-for-recommendation-b94" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b94">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b947acb9-a8f2-4178-92bd-a73924454e7a --><!-- begin field 021a3aab-8810-4507-9a33-fd7382b856ba --><p>These recommendations are largely based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>] and <em>Drug interactions with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017b</a>], and the manufacturers' Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016c</a>]. </p><h5>Extended or tricycling regimen</h5><ul><li>Reducing the number and length of hormone-free intervals means that there is less opportunity for ovulation and follicular development due to falling hormone levels[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012b</a>]. </li><li>Taking two COCs, extended/tricycling regimens and shortening the pill-free interval are all outwith the product licence and there is no evidence that such practice is effective in women taking enzyme-inducing drugs [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012b</a>].</li></ul><!-- end field 021a3aab-8810-4507-9a33-fd7382b856ba --><!-- end item b947acb9-a8f2-4178-92bd-a73924454e7a --></div></section></section><section aria-labelledby="surgery-or-imobilization" class="ChapterBody-module--wrapper--2HCfk "><h3 id="surgery-or-imobilization">What advice on surgery and immobilization should I give to a woman taking a combined oral contraceptive (COC)?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6bb52705-cbe3-444a-8c19-67e3fe96a183 --><!-- begin field 1c16a04c-f38b-4402-91f0-791d83d5d615 --><ul><li>Advise that:<ul><li>No precautions are necessary for minor surgery where the duration of anaesthesia and immobilization is short (such as varicose vein surgery, and tooth extraction). </li><li>The COC should be stopped: <ul><li>Four weeks before any major surgery (which includes operations lasting more than 30 minute), all surgery to the legs, or surgery that involves prolonged immobilization of a lower limb.</li><li>If emergency surgery or immobilization (such as for a leg fracture) is necessary.</li></ul></li><li>If the COC is to be stopped, advise on the use of another suitable method of contraception. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.<ul><li>The COC can be restarted 2 weeks after full mobilization.</li></ul></li></ul></li></ul><!-- end field 1c16a04c-f38b-4402-91f0-791d83d5d615 --><!-- end item 6bb52705-cbe3-444a-8c19-67e3fe96a183 --></div><section aria-labelledby="basis-for-recommendation-14f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-14f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 14fe66bd-da55-41e9-bbb3-375fa8b8ed88 --><!-- begin field fd45092e-9fbb-481e-b0f4-2af459b82bc9 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>].</p><!-- end field fd45092e-9fbb-481e-b0f4-2af459b82bc9 --><!-- end item 14fe66bd-da55-41e9-bbb3-375fa8b8ed88 --></div></section></section><section aria-labelledby="follow-up" class="ChapterBody-module--wrapper--2HCfk "><h3 id="follow-up">What follow up arrangements should I consider for a woman using a combined oral contraceptive?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 96bb0f6d-3f54-45a9-a870-64489b7000f8 --><!-- begin field 18d50c66-ae91-4759-9dd6-d6d5cd0c66c5 --><ul><li>Arrange follow up 3 months after the first prescription of a combined oral contraceptive (COC) pill, and annually thereafter.</li><li>At follow up visits:<ul><li>Check the woman's blood pressure and body mass index.</li><li>Ask about headaches, especially migraine. </li><li>Assess for any new risk factors which may mean COCs are no longer suitable. For more information, see the section on <a class="topic-reference external-reference" href="../../../contraception-assessment/management/assessment-for-specific-contraceptive-methods/index.html#combined-hormonal-contraception">combined hormonal contraception</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.</li><li>Address any issues or adverse effects she has, such as <a class="topic-reference internal-reference" href="index.html#unscheduled-bleeding">unscheduled bleeding</a>.</li><li>Check that the woman is taking the COC correctly and consistently.</li><li>Check the woman's knowledge of what to do if a <a class="topic-reference internal-reference" href="index.html#missed-coc-pills-except-qlaira-zoely">pill is missed</a>, if she has <a class="topic-reference internal-reference" href="index.html#vomiting-diarrhoea">vomiting or diarrhoea</a>, or if she requires <a class="topic-reference internal-reference" href="index.html#surgery-or-imobilization">surgery</a>.</li><li>Remind the woman about possible <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a>.</li><li>Offer verbal and/or written advice about long-acting reversible contraception (copper intrauterine device, levonorgestrel intrauterine system, progestogen-only injectables, progestogen-only implant, and the combined hormonal vaginal ring). For more information, see the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> and <a class="topic-reference external-reference" href="../../../contraception-progestogen-only-methods/index.html">Contraception - progestogen-only methods</a>.</li><li>Advise the woman to return at any time if she has any other issues or concerns.</li></ul></li></ul><!-- end field 18d50c66-ae91-4759-9dd6-d6d5cd0c66c5 --><!-- end item 96bb0f6d-3f54-45a9-a870-64489b7000f8 --></div><section aria-labelledby="duration-of-use" class="ChapterBody-module--wrapper--2HCfk "><h4 id="duration-of-use">How long should the combined oral contraceptive pill be used for?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 275f8051-c594-4289-8f14-a6c0011c05c8 --><!-- begin field 62c6b5d4-6aa7-44c9-a652-a6c0011c0699 --><ul><li>Stop the combined oral contraceptive (COC) at 50 years of age, and switch to one of the following contraceptive methods:<ul><li>A non-hormonal method such as the copper intrauterine device (Cu-IUD).</li><li>The progestogen-only pill (POP), progestogen-only implant, or the levonorgestrel intrauterine system (LNG-IUS). For more information, see the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-ius-iud/index.html">Contraception - IUS/IUD</a> and <a class="topic-reference external-reference" href="../../../contraception-progestogen-only-methods/index.html">Contraception - progestogen-only methods</a>.</li></ul></li></ul><!-- end field 62c6b5d4-6aa7-44c9-a652-a6c0011c0699 --><!-- end item 275f8051-c594-4289-8f14-a6c0011c05c8 --></div></section><section aria-labelledby="basis-for-recommendation-b8f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-b8f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b8f1e34f-0ffd-49da-9e4d-71b5bc3b0cc2 --><!-- begin field a04c85c9-6e40-4432-a093-b9fb1c24479b --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>], <em>Contraception for women aged over 40 years</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2010b</a>], the U<em>K Medical Eligibility Criteria for contraceptive use</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>], and expert opinion in a medical textbook, <em>Contraception today</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guillebaud, 2016</a>].</p><!-- end field a04c85c9-6e40-4432-a093-b9fb1c24479b --><!-- end item b8f1e34f-0ffd-49da-9e4d-71b5bc3b0cc2 --></div></section></section><section aria-labelledby="missed-pill-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="missed-pill-advice">Missed pill advice</h3><section aria-labelledby="missed-coc-pills-except-qlaira-zoely" class="ChapterBody-module--wrapper--2HCfk "><h4 id="missed-coc-pills-except-qlaira-zoely">What advice should I give a woman who has missed pills of combined oral contraceptives (COC), except Qlaira® and Zoely®?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 28a1f693-f55b-425b-9757-a6c001150a10 --><!-- begin field bc9a5d95-a813-4d9c-96f2-a6c001150b65 --><p><strong>These missed pill rules apply to all combined oral contraceptives (COCs) except Qlaira<sup>®</sup> and Zoely<sup>®</sup>.</strong></p><ul><li><strong>If it has been 9 completed days or more since the last active pill was taken when restarting the pill after the hormone-free interval (HFI), consider emergency contraception if unprotected sexual intercourse (UPSI) has taken place during or after the HFI, and advise the woman to:</strong><ul><li>Take the missed pill as soon as possible.</li><li>Continue taking the remaining pills at the usual time.</li><li>Avoid sexual intercourse or use a barrier method of contraception (such as condoms) until 7 consecutive pills have been taken. </li><li>Consider a follow up pregnancy test.</li></ul></li><li><strong>If one pill has been missed (48 to <72 hours since the last pill in the current pack was taken) on week 1 after HFI</strong><strong>, advise the woman:</strong><ul><li>That emergency contraception is not required if there was consistent, correct use earlier in week 1 and the 7 days prior to HFI.</li><li>To take the missed pill as soon as possible.</li><li>To continue taking the remaining pills at the usual time. This may mean taking two pills in 24 hours (the missed pill and the next one at the usual time).</li><li>That no additional contraceptive precautions are required if there was consistent, correct use earlier in week 1 and the 7 days prior to HFI.</li></ul></li><li><strong>If one pill has been missed (48 to <72 hours since the last pill in the current pack was taken) on week 2 or 3 after HFI (or subsequent consecutive weeks of continuous pill-taking)</strong><strong>, advise the woman:</strong><ul><li>That emergency contraception is not required if there was consistent, correct use in the previous 7 days.</li><li>To take the missed pill as soon as possible.</li><li>To continue taking the remaining pills at the usual time. This may mean taking two pills in 24 hours (the missed pill and the next one at the usual time).</li><li>That no additional contraceptive precautions are required if there was consistent, correct use in the previous 7 days.</li></ul></li><li><strong>If 2–7 pills have been missed <strong style="font-size: 19.2px;">(72 hours or more since the last pill in the current pack was taken)</strong> in week 1 after HFI, consider emergency contraception if UPSI has taken place during the HFI or week 1, </strong><strong>advise the woman to:</strong><ul><li>Take the most recent missed pill as soon as possible.</li><li>Continue taking the remaining pills at the usual time. This may mean taking two pills in 24 hours (the most recent missed pill and the next one at the usual time).</li><li>Avoid sexual intercourse or use a barrier method of contraception (such as condoms) until 7 consecutive pills have been taken. </li><li>Consider a follow up pregnancy test.</li></ul></li><li><strong>If 2–7 pills have been missed (72 hours or more since the last pill in the current pack was taken) in week 2 or 3 after HFI (or subsequent consecutive weeks continuous pill-taking),</strong><strong> advise the woman:</strong><ul><li>That emergency contraception is not required if there was consistent, correct use in the previous 7 days.</li><li>To take the most recent missed pill as soon as possible. Any earlier missed pills should be ignored.</li><li>To continue taking the remaining pills at the usual time. This may mean taking two pills in 24 hours (the most recent missed pill and the next one at the usual time).</li><li>That if there were two or more missed pills in the 7 days prior to scheduled HFI, to omit the HFI.   </li><li>To avoid sexual intercourse or use a barrier method of contraception (such as condoms) until 7 consecutive pills have been taken. <ul><li>This is overcautious, but is a back-up in case of subsequent incorrect use. </li></ul></li></ul></li><li><strong>If more than 7 consecutive COC pills have been missed in any week of pill-taking, consider emergency contraception. Advise the woman to:</strong><ul><li>Restart the COC as a new user. See the section on <a class="topic-reference internal-reference" href="index.html#when-to-start">When can a woman start using a combined oral contraceptive?</a> for more information.</li><li>Consider an immediate pregnancy test.</li><li>Quick start a new COC pack (or consider other effective contraception).</li><li>Avoid sexual intercourse or use a barrier method of contraception (such as condoms) until 7 consecutive pills have been taken.</li><li>Consider a follow up pregnancy test.</li></ul></li></ul><!-- end field bc9a5d95-a813-4d9c-96f2-a6c001150b65 --><!-- end item 28a1f693-f55b-425b-9757-a6c001150a10 --></div></section><section aria-labelledby="missed-qlaira-pills" class="ChapterBody-module--wrapper--2HCfk "><h4 id="missed-qlaira-pills">What advice should I give a woman who has missed pills of Qlaira®</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item de001f36-6d21-4aa2-b82f-a6c001152680 --><!-- begin field c2372aaf-c748-4614-b4b4-a6c00115276c --><ul><li>If pill is taken less than 12 hours late, advise the woman:<ul><li>To take the missed pill immediately.</li><li>To take further pills at the usual time.</li><li>That additional contraception is not required.</li></ul></li><li>If pill is taken more than 12 hours late, management will depend on the day of the cycle on which it has been missed. If the missed pill occurs in:<ul><li>Days 1–17, advise the woman to:<ul><li>Take the missed pill immediately and the next pill as usual (even if this means taking 2 pills on the same day).</li><li>Continue with pill taking in the normal way.</li><li>Abstain from sexual intercourse or use an additional contraceptive method (such as condoms) for 9 days.</li></ul></li><li>Days 18–24, advise the woman to:<ul><li>Discard the current packet.</li><li>Start immediately with the first pill of a new packet.</li><li>Continue pill taking in the normal way.</li><li>Abstain from sexual intercourse or use an additional contraceptive method (such as condoms) for 9 days.</li></ul></li><li>Days 25–26, advise the woman to:<ul><li>Take the missed pill immediately and the next pill at the usual time (even if it means taking two tablets on the same day). Additional contraception is not required.</li></ul></li><li>Days 27–28, advise the woman to:<ul><li>Discard the forgotten pill and continue pill taking in the normal way. Additional contraception is not required.</li></ul></li></ul></li><li>Also advise the woman that:<ul><li>No more than 2 pills should be taken in any one day.</li><li>If pills have been missed and no withdrawal bleed occurs at the end of the packet, she should consider the possibility of pregnancy.</li></ul></li></ul><!-- end field c2372aaf-c748-4614-b4b4-a6c00115276c --><!-- end item de001f36-6d21-4aa2-b82f-a6c001152680 --></div></section><section aria-labelledby="missed-zoely-pills" class="ChapterBody-module--wrapper--2HCfk "><h4 id="missed-zoely-pills">What advice should I give a woman who has missed pills of Zoely®</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 966572f6-04ed-457f-8e06-a6c001153ae9 --><!-- begin field d507811e-53c8-4eff-93d2-a6c001153bb7 --><ul><li>If pill is taken less than 24 hours late, advise the woman:<ul><li>To take the missed pill immediately.</li><li>To take further pills at the usual time.</li><li>That additional contraception is not required.</li></ul></li><li>If pill is taken more than 24 hours late, management will depend on the day of the cycle on which it has been missed. If the missed pill occurs in:<ul><li>Days 1–7, advise the woman:<ul><li>To take the missed pill immediately and the next pill as usual (even if this means taking 2 pills on the same day).</li><li>To continue with pill taking in the normal way.</li><li>To abstain from sexual intercourse or use an additional contraceptive method (such as condoms) for 7 days.</li><li>That if unprotected sexual intercourse (UPSI) occurred in the pill-free interval, the possibility of pregnancy should be considered.</li></ul></li><li>Days 8–17, advise the woman:<ul><li>To take the missed pill immediately and the next pill as usual (even if this means taking 2 pills on the same day).</li><li>To continue with pill taking in the normal way.</li><li>That no extra contraception is required provided that the 7 preceding pills have been taken correctly.<ul><li>If more than 1 pill has been missed the woman should abstain from sexual intercourse or use an additional contraceptive method (such as condoms) until she has completed 7 days of uninterrupted white tablet-taking.</li></ul></li><li>That if no withdrawal bleed occurs at the end of the packet, the possibility of pregnancy should be considered.</li></ul></li><li>Days 18–24, consider one of the following two options:<ul><li>Advise the woman to take the missed pill immediately and the next pill at the usual time (even if it means taking 2 tablets on the same day); continue with the active pills in the normal way (pills are active from day 1–24 and inactive from day 25–28); omit the inactive pills and start the next packet of pills. A withdrawal bleed is likely to be absent.</li><li>Advise the woman to discard the remainder of the active pills in the current pack and take the 4 inactive pills in the normal way, then start the next packet of pills. If no withdrawal bleed occurs, the possibility of pregnancy should be considered.</li></ul></li><li>Days 25–28, advise the woman to:<ul><li>Discard the forgotten pill and continue pill taking in the normal way. Additional contraception is not required.</li></ul></li></ul></li></ul><!-- end field d507811e-53c8-4eff-93d2-a6c001153bb7 --><!-- end item 966572f6-04ed-457f-8e06-a6c001153ae9 --></div></section><section aria-labelledby="basis-for-recommendation-4e2" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4e2">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4e22c6c6-658a-4348-8bb1-05999bfbb94d --><!-- begin field 97cc9c46-4312-40b1-9b7f-b2c179d964fa --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Recommended actions after incorrect use of combined hormonal contraception </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2020</a>], <em>Combined hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012a</a>], and the manufacturer's Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016b</a>].</p><!-- end field 97cc9c46-4312-40b1-9b7f-b2c179d964fa --><!-- end item 4e22c6c6-658a-4348-8bb1-05999bfbb94d --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>